Which catheter delivers better chemo to liver tumors? small trial aims to find out

NCT ID NCT06204159

Ongoing Disease control Sponsor: Abramson Cancer Center at Penn Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial compares two FDA-approved catheters used during TACE, a procedure that delivers chemotherapy directly to liver tumors. Twelve participants with liver cancer or neuroendocrine tumors will receive two TACE procedures, each using a different catheter. The goal is to see which catheter provides better coverage of the tumor with the chemotherapy agent Lipiodol, as seen on CT scans.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lipiodol (chemotherapy delivery agent) via TACE procedure
What this could lead to: If successful, this could help doctors choose the best catheter for delivering chemotherapy directly to liver tumors, potentially improving treatment effectiveness.
What could go wrong: This is a very small, early-stage study (12 participants) comparing two already-approved devices. It may not show a clear difference or lead to changes in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA NEUROENDOCRINE TUMORS

Contacts and locations

Locations

Abramson Cancer Center of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
University of Pennsylvania, Department of Radiology, Interventional Radiology Division

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.